cGAS-Targeted Compounds to Reduce Chronic Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The hyperactivation of the cGAS/STING pathway leads to chronic inflammation and tissue damage in various diseases, including autoimmune and inflammatory disorders, for which current treatments are inadequate.
Innovation Solution
Development of compounds that inhibit the cGAS pathway, specifically targeting cGAS, to reduce inflammatory cytokine production and ameliorate associated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the cGAS/STING pathway is hyperactivated to recognize cytosolic dsDNA, then immune response is enhanced, but chronic inflammation and tissue damage occur
Solution Approach 1:
The patent applies parameter changes by developing small molecule compounds that modulate the activity of cGAS or STING proteins. These compounds change the activation threshold or signaling intensity of the cGAS/STING pathway, allowing it to respond appropriately to cytosolic dsDNA while preventing hyperactivation that leads to chronic inflammation. The compounds achieve this by altering the biochemical parameters of pathway components, such as binding affinity or catalytic activity.
Solution Approach 2:
The patent uses small molecule compounds as intermediaries to regulate the interaction between cGAS/STING and cytosolic dsDNA. These compounds act as mediators that can either enhance or suppress pathway activation depending on the physiological context. By introducing these chemical intermediaries, the system can distinguish between appropriate immune responses and pathological hyperactivation, thereby preventing tissue damage while maintaining immune surveillance.
2Reliability
If current treatments are used for autoimmune and inflammatory disorders, then some symptoms are managed, but inadequate treatment efficacy and side effects persist
Solution Approach 1:
The patent extracts the specific pathological mechanism of cGAS/STING hyperactivation from the broader context of autoimmune and inflammatory diseases. By identifying and targeting this specific pathway with selective small molecule compounds, the treatment addresses the root cause of chronic inflammation without broadly suppressing the immune system. This extracted, targeted approach improves efficacy while reducing side effects compared to conventional broad-spectrum immunosuppressants.
Solution Approach 2:
The patent replaces mechanical or broad pharmacological interventions with precisely designed small molecule compounds that target specific molecular interactions in the cGAS/STING pathway. Instead of using non-specific anti-inflammatory drugs that affect multiple pathways, the invention uses chemically engineered molecules with high selectivity for their molecular targets, substituting brute-force pharmacology with precision molecular medicine.
Data Source
AI summary
The present disclosure relates to a compound of Formula (I):or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, wherein R1 through R8 are as defined herein, and methods of making and using the same.